GT
BIOA

Glenmede Trust’s BioAge Labs BIOA Stock Holding History

Glenmede Trust’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$269K Buy
+10,960
New +$198K ﹤0.01% 1223

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Glenmede Trust's BIOA Position: Q2 2026 in Review

Glenmede Trust opened a new position in BioAge Labs (BIOA) in Q2 2026: 10,960 shares worth $269K. The stake represents ﹤0.01% of the portfolio and ranks #1223 among its holdings.

151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Glenmede Trust held 10,960 shares of BioAge Labs worth $269K as of Q2 2026.
  • BioAge Labs was a new Glenmede Trust position in Q2 2026.
  • BioAge Labs made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1223 holding.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.